Key Highlights
- Helaina raises $45M in Series B funding, bringing total equity to $83M.
- Led by Avidity Partners with support from Spark Capital and other key investors.
- Funding to scale effera™ Human Lactoferrin for women’s health, active nutrition, and aging.
- Effera™ will be available through Kroma Wellness, The Feed, Levelle Nutrition, and Mitsubishi International Food Ingredients.
- Helaina’s technology supports iron metabolism, immune response, and microbiome health.
Source: Business Wire
Notable Quotes
- “At this pivotal moment in our company’s journey, we’re proud to partner with Avidity Partners, an investment firm with an outstanding reputation for supporting best-in-class biotechnology companies rooted in clinically-backed science.” — Laura Katz, CEO and Founder at Helaina
- “We are thrilled to support Helaina’s innovative approach to nutrition, which aligns with pressing health and wellness priorities, from immune system support to fostering a balanced gut microbiome.” — Jacob Garfield, Managing Director at Avidity
SoHC's Take
Helaina’s recent funding demonstrates significant confidence in biotechnology solutions that address growing demands for functional foods and supplements. With the scaling of effera™ Human Lactoferrin, Helaina is well-positioned to transform the nutritional landscape, especially for women’s health and aging. Their strategic partnerships and innovation in precision fermentation reinforce the company’s role as a leader in advancing human healthspan.
